Last reviewed · How we verify

Full course of PD-1blockades

Ming-Yuan Chen · Phase 3 active Small molecule

Full course of PD-1blockades is a PD-1 inhibitor Small molecule drug developed by Ming-Yuan Chen. It is currently in Phase 3 development for Metastatic melanoma, Non-small cell lung cancer, Renal cell carcinoma.

PD-1 blockade inhibits the programmed death-1 checkpoint, allowing T cells to recognize and attack cancer cells.

PD-1 blockade inhibits the programmed death-1 checkpoint, allowing T cells to recognize and attack cancer cells. Used for Metastatic melanoma, Non-small cell lung cancer, Renal cell carcinoma.

At a glance

Generic nameFull course of PD-1blockades
SponsorMing-Yuan Chen
Drug classPD-1 inhibitor
TargetPD-1
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

PD-1 inhibitors bind to the PD-1 receptor on T cells, blocking interaction with PD-L1/PD-L2 ligands expressed on tumor cells and immune cells. This releases the 'brakes' on anti-tumor immunity, restoring T cell proliferation, activation, and cytotoxic function. A full course typically involves multiple doses administered over several months to achieve sustained immune activation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Full course of PD-1blockades

What is Full course of PD-1blockades?

Full course of PD-1blockades is a PD-1 inhibitor drug developed by Ming-Yuan Chen, indicated for Metastatic melanoma, Non-small cell lung cancer, Renal cell carcinoma.

How does Full course of PD-1blockades work?

PD-1 blockade inhibits the programmed death-1 checkpoint, allowing T cells to recognize and attack cancer cells.

What is Full course of PD-1blockades used for?

Full course of PD-1blockades is indicated for Metastatic melanoma, Non-small cell lung cancer, Renal cell carcinoma, Hodgkin lymphoma, Head and neck squamous cell carcinoma.

Who makes Full course of PD-1blockades?

Full course of PD-1blockades is developed by Ming-Yuan Chen (see full Ming-Yuan Chen pipeline at /company/ming-yuan-chen).

What drug class is Full course of PD-1blockades in?

Full course of PD-1blockades belongs to the PD-1 inhibitor class. See all PD-1 inhibitor drugs at /class/pd-1-inhibitor.

What development phase is Full course of PD-1blockades in?

Full course of PD-1blockades is in Phase 3.

What are the side effects of Full course of PD-1blockades?

Common side effects of Full course of PD-1blockades include Fatigue, Diarrhea, Nausea, Immune-related pneumonitis, Immune-related hepatitis, Immune-related colitis.

What does Full course of PD-1blockades target?

Full course of PD-1blockades targets PD-1 and is a PD-1 inhibitor.

Related